CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) insider Dennis D. Kim sold 112,219 shares of the business’s stock in a transaction that occurred on Monday, April 17th. The shares were sold at an average price of $9.54, for a total value of $1,070,569.26. Following the completion of the sale, the insider now directly owns 20,000 shares of the company’s stock, valued at approximately $190,800. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of CBAY opened at $9.84 on Wednesday. The firm has a market cap of $957.33 million, a PE ratio of -8.13 and a beta of 0.27. CymaBay Therapeutics, Inc. has a 1 year low of $1.67 and a 1 year high of $10.25. The stock’s fifty day moving average price is $8.66 and its two-hundred day moving average price is $6.15.

CymaBay Therapeutics (NASDAQ:CBAY – Get Rating) last released its quarterly earnings results on Thursday, March 16th. The biopharmaceutical company reported ($0.30) EPS for the quarter, meeting analysts’ consensus estimates of ($0.30). During the same period in the prior year, the business posted ($0.34) EPS.  Sell-side analysts anticipate that  CymaBay Therapeutics, Inc. will post -0.93 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Raymond James & Associates lifted its stake in  CymaBay Therapeutics by 26.3% in the first quarter. Raymond James & Associates now owns 97,604 shares of the biopharmaceutical company’s stock worth $304,000 after purchasing an additional 20,337 shares during the last quarter.  Bank of New York Mellon Corp raised its position in shares of  CymaBay Therapeutics by 8.6% in the first quarter. Bank of New York Mellon Corp now owns 276,766 shares of the biopharmaceutical company’s stock worth $861,000 after acquiring an additional 21,961 shares during the period.  MetLife Investment Management LLC acquired a new position in shares of  CymaBay Therapeutics during the 1st quarter worth about $163,000.  BlackRock Inc. lifted its stake in  CymaBay Therapeutics by 2.7% in the 1st quarter. BlackRock Inc. now owns 5,466,209 shares of the biopharmaceutical company’s stock valued at $16,998,000 after buying an additional 142,081 shares in the last quarter.  Finally, Dimensional Fund Advisors LP lifted its stake in  CymaBay Therapeutics by 18.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 940,806 shares of the biopharmaceutical company’s stock worth $2,926,000 after purchasing an additional 145,965 shares in the last quarter. 73.54% of the stock is owned by institutional investors.

CBAY has been the subject of a number of recent analyst reports. BTIG Research assumed coverage on CymaBay Therapeutics in a research report on Thursday, March 9th. They set a “buy” rating and a $15.00 target price for the company. HC Wainwright increased their price objective on CymaBay Therapeutics from $10.00 to $12.00 in a research note on Friday, March 17th. William Blair initiated coverage on CymaBay Therapeutics in a research note on Wednesday, April 5th. They set an “outperform” rating for the company. Raymond James increased their target price on CymaBay Therapeutics from $14.00 to $17.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 17th. Finally, Cantor Fitzgerald raised their price target on CymaBay Therapeutics from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Tuesday, January 31st. One analyst  has rated the stock with a hold rating, seven have issued  a buy rating and one  has given a strong buy rating to the company. According to MarketBeat.com, CymaBay Therapeutics presently has a consensus rating of “Buy” and an average price target of $13.50.

CymaBay Therapeutics, Inc engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.